Abstract

Using in vitro drug sensitivity data coupled with Affymetrix microarray data, we developed gene expression signatures that predict sensitivity to individual chemotherapeutic drugs. Each signature was validated with response data from an independent set of cell line studies. We further show that many of these signatures can accurately predict clinical response in individuals treated with these drugs. Notably, signatures developed to predict response to individual agents, when combined, could also predict response to multidrug regimens. Finally, we integrated the chemotherapy response signatures with signatures of oncogenic pathway deregulation to identify new therapeutic strategies that make use of all available drugs. The development of gene expression profiles that can predict response to commonly used cytotoxic agents provides opportunities to better use these drugs, including using them in combination with existing targeted therapies.

NOTE: In the version of this article initially published online, the affiliations of some authors were incorrectly listed. R.S. and J.C. should be affiliation 4, and the correct address for this affiliation should be Division of Gynecologic Surgical Oncology, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, 12902 Magnolia Drive, Tampa, Florida 33612, USA. Also, "Center for Applied Genomics and Technology" should be omitted from affiliation 1. The error has been corrected for all versions of the article.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.